(Q33703387)

English

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer (English)

1 reference

Europe PubMed Central

28 July 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

20

object named as

Jeffrey Schlom

1 reference

Europe PubMed Central

28 July 2017

James L. Gulley

1

object named as

James L Gulley

1 reference

Europe PubMed Central

28 July 2017

Seth M Steinberg

13

object named as

Seth M Steinberg

1 reference

Europe PubMed Central

28 July 2017

19

object named as

William L Dahut

1 reference

Europe PubMed Central

28 July 2017

author name string

Philip M Arlen

2

1 reference

Europe PubMed Central

28 July 2017

Ravi A Madan

3

1 reference

Europe PubMed Central

28 July 2017

Kwong-Yok Tsang

4

1 reference

Europe PubMed Central

28 July 2017

Mary P Pazdur

5

1 reference

Europe PubMed Central

28 July 2017

Lisa Skarupa

6

1 reference

Europe PubMed Central

28 July 2017

Jacquin L Jones

7

1 reference

Europe PubMed Central

28 July 2017

Diane J Poole

8

1 reference

Europe PubMed Central

28 July 2017

Jack P Higgins

9

1 reference

Europe PubMed Central

28 July 2017

James W Hodge

10

1 reference

Europe PubMed Central

28 July 2017

Vittore Cereda

11

1 reference

Europe PubMed Central

28 July 2017

Matteo Vergati

12

1 reference

Europe PubMed Central

28 July 2017

Susan Halabi

14

1 reference

Europe PubMed Central

28 July 2017

Elizabeth Jones

15

1 reference

Europe PubMed Central

28 July 2017

Clara Chen

16

1 reference

Europe PubMed Central

28 July 2017

Howard Parnes

17

1 reference

Europe PubMed Central

28 July 2017

John J Wright

18

1 reference

Europe PubMed Central

28 July 2017

publication date

5 November 2009

1 reference

Europe PubMed Central

28 July 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

28 July 2017

59

1 reference

Europe PubMed Central

28 July 2017

5

1 reference

Europe PubMed Central

28 July 2017

663-674

1 reference

Europe PubMed Central

28 July 2017

https://scigraph.springernature.com/pub.10.1007/s00262-009-0782-8

0 references

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

Vaccines with enhanced costimulation maintain high avidity memory CTL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

Multiple costimulatory modalities enhance CTL avidity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

21 June 2018

Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

30 October 2018

Clinical safety of a viral vector based prostate cancer vaccine strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

30 October 2018

Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

30 October 2018

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

30 October 2018

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

30 October 2018

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

30 October 2018

Vaccine therapy of established tumors in the absence of autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

30 October 2018

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

30 October 2018

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

30 October 2018

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832083

30 October 2018

A triad of costimulatory molecules synergize to amplify T-cell activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19890632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant

1 reference

https://pubmed.ncbi.nlm.nih.gov/19890632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/19890632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19890632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00262-009-0782-8

1 reference

Europe PubMed Central

28 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33703387&oldid=1856098299"